Earli

Force Cancer To Reveal Itself Early, Then Cure It.

Founded by Stanford physician-scientists and serial entrepreneurs, Earli is developing a radically new technology that forces cancer cells to make Synthetic Biomarkers that do not belong in the human body, which can then be detected, localized and ultimately cured.

Programs

Earli is actively seeking an Assay Development Scientist, a Scientific Project Manager and starting early conversations with Senior Bioinformatics Scientists to join their team through our programs.

Apply More about the program

Highlights

Searching for early cancer DNA is like looking for one drop in an ocean.

40% of us will develop cancer in our lifetime, and a third will die from it. For cancers that cause the highest number of deaths every year, if we can detect them at stage 1 instead of stage 4, patients have a 4 to 14 times higher 5-year survival rate.

Traditional early cancer detection techniques focus on finding natural biomarkers shed by cancer into the bloodstream. However, in practice, it is extremely difficult to find the very small amounts of early cancer cell DNA, with trillions of other similar-looking cell DNA around.

Earli's Product & Vision

Instead of searching for hard-to-detect natural biomarkers, Earli is developing a radically new technique which forces cancer cells to produce synthetic biomarkers. These synthetic biomarkers do not naturally exist in the human body, therefore are easy to detect and quantify. The same platform can be used to localize and ultimately cure early cancers. With the introduction of this technique, Earli is starting a new era of “synthetic biomarkers.”

The science behind Earli was originally developed by Dr. Sam Gambhir, who runs Stanford’s Canary Center for Early Cancer Detection.

Earli's mission is to make cancer a benign experience, by catching and curing it early.

Founders & Founding Story

Dr. Sam Gambhir’s wife Aruna had developed breast cancer and survived it. Then his only 15-year old son Milan developed brain cancer. Meanwhile Sam was urgently searching for new ways to detect and treat cancer. As the founder of Stanford’s Canary Center of Early Cancer Detection, and head of Radiology at the Stanford Clinic, he was looking at natural cancer biomarkers in blood; they were promising but proving elusive. So Sam flipped the problem on its head and came up with a radically new idea. Four years of lab work ensued to make it work in mice. The solution came too late for his beloved Milan. This deep loss gave Sam a sense of purpose against all odds.

On Thanksgiving Day, Cyriac Roeding, who had sold his previous startup, read Sam’s gripping story and contacted him. He had looked at 200 ideas to find the right next challenge on the intersection of the physical and engineering world. But he had not been as deeply touched by any other mission like Sam’s. The two met on a Saturday morning for breakfast at a local restaurant to talk. It turned out, they lived one minute from each other.

Sam’s and Cyriac’s Saturday morning breakfast in their local 4,000 people town in Silicon Valley turned into a 3-hour conversation, and not long after, Cyriac found himself at Sam’s house every other Saturday morning for the next three months, where Sam told the entrepreneur about biology and oncology insights. Sam shared with him his idea of Synthetic Biomarkers, forcing the cancer to produce a non-human substance to help reveal, then localize and ultimate destroy itself. Cyriac was immediately fascinated and could not forget about the idea. For the next nine months, they went through hundreds of people to find the right third co-founder and Chief Scientific Officer. That became David Suhy, a gene therapy and bio startup expert with experience taking a gene therapy product all the way from inception to Phase 2 clinical trials. Earli was born in June 2018 and moved into its first lab space in South San Francisco a month later.

Now Earli is building the world’s best team to bring the science to humans as soon as possible and fulfill Sam’s deep purpose.